Breakthrough cancer therapies are transforming survival rates globally, yet in South Africa, life-saving innovations remain largely out of reach. While public sector patients face severely constrained provincial budgets, private medical scheme members are confronted by outdated statutory frameworks, restrictive plan tiers, and devastating out-of-pocket co-payments.
From the complex procurement of essential drugs like trastuzumab to high-cost immunotherapies costing tens of thousands of rands per dose, systemic funding challenges continue to leave vulnerable patients navigating complex bureaucracy at their most critical hour.
Subscriber access
There’s more to this story.
Sign in to continue reading. This article is reserved for subscribers. New here? Create an account to get started.